Sentences with phrase «called epidermal growth factor receptor»

This growth factor binds to something called the Epidermal Growth Factor Receptor (EGFR), which stimulates the pilosebaceous unit (the follicle) to overproduce sebum (mixture of natural skin oils and skin cells), which can lead to acne lesions.

The Alabama scientists have now shown how it works against head and neck cancers: It blocks a protein called epidermal growth factor receptor, or EGFR.

Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well - known «resistance» mutations in the gene called epidermal growth factor receptor (EGFR).

That protein, CRKII, interacts with another protein called an epidermal growth factor receptor.

Not exact matches

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

The study, called the PALOMA - 3, enrolled 521 pre - / peri - and postmenopausal patients with hormone receptor positive and human epidermal growth factor receptor - negative (HR + / HER2 --RRB- advanced disease.

The analysis also found that Asian / Pacific Islander women were more likely to be diagnosed with another subtype of breast cancer: so - called human epidermal growth factor receptor 2 (HER2)- overexpressing breast cancer.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

Triple - negative cancers are so called because they do not express receptors for the hormones estrogen and progesterone, nor for HER2 (human epidermal growth factor 2), and hence patients with these cancers are not candidates for treatment with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

Others respond to another protein called human epidermal growth factor receptor 2, or HER2.

Epidermal growth factor receptor, also called EGFR, is a biomarker found in certain patients with lung cancer.

Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).